Product Code: RP-ID-10085881 |
Published Date: 21 Mar 2025 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10085881
Market Overview:
Global Epilepsy Market Segmentation by End-Use (Diagnostic Centers, Hospitals, Clinics, Ambulatory Surgical Centers, and Others); and by Treatment & Diagnosis (Treatment, and Diagnosis)-Global Demand Analysis & Opportunity Outlook 2031
Global Epilepsy Market Highlights Over 2022 – 2031
The global epilepsy market is estimated to grow with a CAGR of ~8% over the forecast period, i.e., 2022 – 2031. Moreover, the market registered a notable revenue in the year 2021. The growth of the market can be attributed to the increase in the aged population that is more prone to epilepsy disorder as compared to the younger generation. Moreover, there has been growing awareness related to epilepsy among people which is also anticipated to drive market growth. According to the World Health Organization, approximately 50 million people across the globe are suffering from epilepsy disorder with nearly 80 percent of them are living in middle- and low-income countries.
GET A SAMPLE COPY OF THIS REPORT
The COVID-19 pandemic had a negative impact on people suffering with epilepsy. The healthcare facilities were limited to COVID-19-infected patients owing to the risk of disease transfer from one person to another. Moreover, the pandemic is known to worsen the health conditions of epilepsy patients considering the symptoms such as fever, tiredness, and cough. Therefore, the demand for epilepsy care increased during the pandemic.
The global epilepsy market is segmented by treatment & diagnosis into treatment and diagnosis. Out of these, the diagnosis segment is anticipated to hold the largest share over the forecast period in the global epilepsy market. This can be attributed to the rise in awareness among people for early diagnosis of epilepsy in the form of blood and imaging tests that can help in finding out the abnormality in the brain.
Global Epilepsy Market Regional Synopsis
Regionally, the global epilepsy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. On the strength of the presence of healthcare-supportive government policies and established healthcare infrastructure, the market in the North America region is anticipated to hold the largest share by the end of 2031. Moreover, the market in Asia Pacific region is estimated to witness modest growth over the forecast period on the back of an increase in the aged population, increase in healthcare expenditure, and a rise in spending on research and development. As per the World Bank, the percentage of the population aged 65 and above increased from 3% of the total population in 1960 to 7% of the total population in 2020.
Market Segmentation
Our in-depth analysis of the global epilepsy market includes the following segments:
By End-Use
-
Diagnostic Centers
-
Hospitals
-
Clinics
-
Ambulatory Surgical Centers
-
Others
By Treatment & Diagnosis
-
Treatment
-
Diagnosis
Growth Drivers and Challenges Impacting the Growth of the Global Epilepsy Market
Growth Drivers
-
Increase in the aged population
-
Rise in the awareness related to epilepsy
Challenges
-
Increasing cost of medicine
-
Lack of skilled healthcare workers
Key Companies Dominating the Global Epilepsy Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global epilepsy market that are included in our report are NeuroPace, Inc., Pfizer Inc., LivaNova PLC, Abbott., Jazz Pharmaceuticals plc (GW Pharmaceuticals), Novartis AG, Johnson & Johnson Services, Inc., Medtronic, Eisai Co., Ltd., GlaxoSmithKline plc., and others.
Latest Developments in the Global Epilepsy Market:
-
31 August 2020: NeuroPace, Inc., announced it has raised USD 67 million in funding to support the commercialization of the RNS System for Refractory Epilepsy.
-
1 April 2022: Eisai Co., Ltd. announced the acquisition of Arteryex Inc., to strengthen to rapidly expand and strengthen the foundation of its digital solution business in the field of healthcare.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
- NeuroPace, Inc.
- Pfizer Inc.
- LivaNova PLC
- Abbott.
- Jazz Pharmaceuticals plc (GW Pharmaceuticals)
- Novartis AG
- Johnson & Johnson ServicesInc.
- Medtronic
- Eisai Co.Ltd.
- GlaxoSmithKline plc.
Related Reports
Proof of Quality & Reliability
